Drugs / CUDC-101
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01702285 | Sep → Dec 2012 | cancer | Curis, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01384799 | Nov 2011 → Sep 2013 | head and neck cancer | Curis, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01171924 | Jul 2010 → Oct 2011 | breast cancer, gastric cancer, head and neck cancer, liver cancer +1 | Curis, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00728793 | Aug 2008 → Apr 2010 | neoplasm | Curis, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUDC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01702285 ↗ |
| Action | Inhibit | “designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2(Her2) and histone deacetylase (HDAC)” NCT00728793 ↗1“Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL598797 ↗ |
| Modality | Small molecule | — CHEMBL598797 ↗ |
| Route | Intravenous | “Doses will be given by intravenous infusion over 1 hour” NCT00728793 ↗ |
| Target | EGFR | “inhibit epidermal growth factor receptor (EGFR)” NCT00728793 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL598797 ↗ |